4612

Novel Nasal Delivery of Cannabinoid Formulations

Touitou Elka, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research

Keywords

Innovative carrier, Nasal administration, Delivery to brain, Treatment of pain, disorders in Parkinson's disease, Multiple Sclerosis, Alzheimer, Epilepsy and brain trauma

Current development stage

Tested in animal model for pain

Seeking to license the technology

Our innovation

Phospholipid Magnesome carrier has the ability to deliver central acting drugs, peptides, proteins, siRNA and such to brain. It was shown by successful delivery of insulin, oxytocin, EGF and drugs for treating pain, disorders in Parkinson's disease, Multiple Sclerosis, Alzheimer, Epilepsy and brain trauma.  

Advantages

  • Rapid onset of action – for treatment of Pain, Rigidity in Parkinson’s disease.
  • Can increase efficiency and patient compliance by avoiding invasive treatments.
  • Opens a way for new strategies for treatment of brain and CNS diseases.
  • Delivery to Brain Visualized by NIR Imaging and Semi-Quantified

4612.jpg 

Figure 1  Representative NIR images and semi-quantification of fluorescence intensity in mice brains treated nasally with Epidermal Growth Factor (EGF) IRDye  from Phospholipid Magnesome, as compared to water solution (WS), Liposome (Lipo) and nonvesicular system (NV); Mean±SD, n=3/ group. Odyssey® Infrared Imaging System, LI-COR, USA

 

Contact for more information:

Ariela Markel
VP, Business Development, Healthcare
+972-2-6586608
Contact ME:
Image CAPTCHA